BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37147968)

  • 1. Early endometrial carcinoma: Experience and outcomes.
    Goel P; Singh V; Sharma R; Chaudhary D; Chatterjee A; Dora T; Sancheti S; Goel A; Khandelwal S; Sali AP; Kaur H; Guru A; Kapoor R
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
    Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
    J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of adjuvant radiotherapy in FIGO stage IIIC endometrial carcinoma: Treatment outcomes and prognostic factors in 52 irradiated patients.
    Hsieh HY; Wang L; Lu CH; Lin JC; Chen CC
    J Formos Med Assoc; 2018 Jul; 117(7):613-620. PubMed ID: 28867455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion.
    Bendifallah S; Canlorbe G; Raimond E; Hudry D; Coutant C; Graesslin O; Touboul C; Huguet F; Cortez A; Daraï E; Ballester M
    Br J Cancer; 2014 May; 110(11):2640-6. PubMed ID: 24809776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.
    Liang LW; Perez AR; Cangemi NA; Zhou Q; Iasonos A; Abu-Rustum N; Alektiar KM; Makker V
    Int J Gynecol Cancer; 2016 Mar; 26(3):497-504. PubMed ID: 26825840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group.
    Reboux PA; Azaïs H; Canova CH; Bendifallah S; Ouldamer L; Raimond E; Hudry D; Coutant C; Graesslin O; Touboul C; Collinet P; Bricou A; Huchon C; Daraï E; Ballester M; Lévêque J; Lavoué V; Koskas M; Uzan C; Canlorbe G
    J Gynecol Oncol; 2019 Jul; 30(4):e53. PubMed ID: 31074238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution.
    Kumar UP; Yathiraj PH; Sharan KT; Kamath A; Singh A; Reddy SA; Alurkar P; Fernandes DJ; Mamidipudi VS
    Int J Gynecol Cancer; 2018 Jun; 28(5):854-860. PubMed ID: 29683879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of early-stage endometroid adenocarcinoma: a tertiary cancer center experience.
    Mahantshetty U; Aggarwal A; Ganesh B; Saoba S; Mulla S; Engineer R; Chopra S; Maheshwari A; Kerkar R; T S S; Ghosh J; Gupta S; Shrivasatava S
    Int J Gynecol Cancer; 2013 Oct; 23(8):1446-52. PubMed ID: 24257559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
    de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
    Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
    Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
    Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
    Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
    Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of recurrence in patients with endometrial cancer: A retrospective study.
    Vizza E; Cutillo G; Bruno V; Sperduti I; Mancini E; Baiocco E; Chiofalo B; Cicchillitti L; Certelli C; Zampa A; Piccione E; Corrado G
    Eur J Surg Oncol; 2020 Sep; 46(9):1697-1702. PubMed ID: 32204935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
    Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
    Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
    Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
    Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of complete surgical staging on adjuvant treatment decisions in endometrial cancer.
    Goudge C; Bernhard S; Cloven NG; Morris P
    Gynecol Oncol; 2004 May; 93(2):536-9. PubMed ID: 15099975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of disease recurrence between robotic versus laparotomy approach in patients with intermediate-risk endometrial cancer.
    Song J; Le T; Hopkins L; Fung-Kee-Fung M; Lupe K; Gaudet M; E C; Samant R
    Int J Gynecol Cancer; 2020 Feb; 30(2):160-166. PubMed ID: 31871112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer.
    Long KC; Zhou Q; Hensley ML; Alektiar KM; Gomez J; Gardner GJ; Chi DS; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2012 Apr; 125(1):99-102. PubMed ID: 22112609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age as a continuous variable in early-stage endometrial carcinoma: a multi-institutional analysis in China.
    Sun S; Zou L; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Wang W; Jin M; Zhang F; Hou X; Wei L; Hu K
    Aging (Albany NY); 2021 Aug; 13(15):19561-19574. PubMed ID: 34371481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes and patterns of failure in women with stage IIIC
    Lee JK; Mahan M; Hanna RK; Elshaikh MA
    Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():192-197. PubMed ID: 28800504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline risk of recurrence in stage I-II endometrial carcinoma.
    Sasada S; Yunokawa M; Takehara Y; Ishikawa M; Ikeda S; Kato T; Tamura K
    J Gynecol Oncol; 2018 Jan; 29(1):e9. PubMed ID: 29185267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.